Cardiovascular risk assessment and lipid modification

or changing treatment. Adults taking medicine to reduce their chance of a heart attack or stroke have a blood test 2 to 3 months after starting or changing medicine to check that it is reducing their cholesterol levels and not affecting their liver. Source guidance Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline NG238 (2023), recommendation 1.11.1 Definitions of terms used in this quality statement Full lipid profile This involves taking a blood sample to measure total cholesterol, HDL cholesterol and triglyceride levels and then calculating non-HDL cholesterol and LDL cholesterol (a fasting sample is not mandated). LDL cholesterol results may not be reported in participants with triglyceride levels more than 4.5 mmol per litre or 9 mmol per litre depending on the formula used by local laboratories. [NICE's guideline on cardiovascular disease: risk assessment and reduction, including lipid modification, terms used in this guideline] Quality statement 5: Secondary prevention of cardiovascular disease Quality statement Adults with cardiovascular disease have a low-density lipoprotein (LDL) cholesterol level of 2.0 mmol per litre or less, or a non-high-density lipoprotein (non-HDL) cholesterol level of 2.6 mmol per litre or less. [new 2025] Rationale Management of LDL cholesterol or non-HDL cholesterol
